Eugene Athan

11.8k citations
143 papers · 3.7k · 1 hit paper · h-index 35

Impact in

  • Infectious Diseases top 1%
    • Antimicrobial Resistance in Staphylococcus
    • Tuberculosis Research and Epidemiology
  • Epidemiology top 1%
    • Mycobacterium research and diagnosis
    • Infective Endocarditis Diagnosis and Management

Papers in

  • Epidemiology 69
    • Mycobacterium research and diagnosis 37
    • Infective Endocarditis Diagnosis and Management 16
  • Infectious Diseases 49
    • Tuberculosis Research and Epidemiology 13
    • Antimicrobial Resistance in Staphylococcus 9
Co-authors
D. O’Brien (45 shared papers)N. Deborah Friedman (24 shared papers)Anthony McDonald (14 shared papers)Andrew Hughes (14 shared papers)Andrew Hughes (11 shared papers)Peter Callan (13 shared papers)Aaron Walton (12 shared papers)Allen Cheng (11 shared papers)
Journals
The Medical Journal of Australia (14 papers)PLoS neglected tropical diseases (9 papers)BMC Infectious Diseases (8 papers)Emerging infectious diseases (8 papers)Clinical Infectious Diseases (5 papers)
Partner nations
AustraliaUnited StatesUnited Kingdom

In The Last Decade

Eugene Athan

137 papers receiving 3.5k citations

Eugene Athan's Hit Papers

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial 2025 · 20 citations
200Years since publication5101520
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2025 The Lancet Respiratory Medicine

Peers

Eugene Athan
Comparison fields: 5 of 135
  • Infectious Diseases 1.3k
  • Epidemiology 1.9k
  • Small Animals 448
  • Applied Microbiology and Biotechnology 108
  • Molecular Medicine 199
Replace Robert Krause with:
Robert Krause Austria
Fehmı Tabak Türkiye
Antonio Arrieta United States
Jihad Bishara Israel
Sang‐Oh Lee South Korea
D. Rebecca Prevots United States
Hee Jin Cheong South Korea
V. Ausina Spain
I. W. Fong Canada
Roberto Luzzati Italy
Eugene Athan relative to Robert Krause Austria Robert Krause's profile →
Citations per field
00.5×1.5×2.0×
Robert Krause · 1×
Citations per year

Countries citing papers authored by Eugene Athan

Since Specialization
Citations

This map shows the geographic impact of Eugene Athan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene Athan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene Athan more than expected).

Fields of papers citing papers by Eugene Athan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugene Athan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene Athan. The network helps show where Eugene Athan may publish in the future.

Co-authors

The 25 scholars most cited alongside Eugene Athan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eugene Athan Line = papers co-authored together Eugene Athan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 143 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis
Circulation ·Vivian H. Chu, Lawrence P. Park, Eugene Athan, François Delahaye, Tomáš Freiberger, Cristiane da Cruz Lamas, José M. Miró, Daniel W. Mudrick, Jacob Strahilevitz, Christophe Tribouilloy, Emanuele Durante‐Mangoni, Juan M. Pericàs, Nuria Fernández‐Hidalgo, Francisco Nacinovich, Hussien Rizk, Vladimir Krajinović, Efthymia Giannitsioti, John P. Hurley, Margaret M. Hannan, Andrew Wang
2014192
2
Emergence of Coagulase-Negative Staphylococci as a Cause of Native Valve Endocarditis
Clinical Infectious Diseases ·Vivian H. Chu, Christopher W. Woods, José M. Miró, Bruno Hoen, Christopher H. Cabell, Paul Pappas, Jerome J. Federspiel, Eugene Athan, Martín E. Stryjewski, F. Nacinovich, Francesc Marco, Donald P. Levine, Thomas Elliott, Cláudio Querido Fortes, Pilar Tornos, David Gordon, Riccardo Utili, François Delahaye, G. Ralph Corey, Vance G. Fowler
2007138
3
Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis
Gut Microbes ·Jessica Green, Jessica A. Davis, Michael Berk, Christopher Hair, Amy Loughman, David Castle, Eugene Athan, Andrew A. Nierenberg, John F. Cryan, Felice N. Jacka, Wolfgang Marx
2020117
4
Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study
Clinical Microbiology and Infection ·Catherine Chirouze, Eugene Athan, François Alla, Vivian H. Chu, G. Ralph Corey, Christine Selton‐Suty, M.-L. Erpelding, José M. Miró, Lars Olaison, Bruno Hoen
2013116
5
Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand
Internal Medicine Journal ·Jason A. Trubiano, Allen Cheng, Tony M. Korman, Christine Röder, Anita J Campbell, Meryta May, Christopher C. Blyth, John Ferguson, Timothy Blackmore, Thomas V. Riley, Eugene Athan
201689
6
Risk Factors forMycobacterium ulceransInfection, Southeastern Australia
Emerging infectious diseases ·Tricia Quek, Eugene Athan, Margaret J. Henry, Julie A. Pasco, Jane Redden‐Hoare, Andrew Hughes, Paul D. R. Johnson
200788
7
Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment
PubMed ·Nikhil Sathe, Peter L. Beech, Larry Croft, Cenk Suphioglu, A. Kapat, Eugene Athan
202387
8
Pacemaker Infections: A 10-Year Experience
Heart Lung and Circulation ·Andrei Catanchin, Challon J. Murdock, Eugene Athan
200777
9
Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy
Antimicrobial Agents and Chemotherapy ·Christopher Arnold, Melissa D. Johnson, Arnold S. Bayer, Suzanne Bradley, Efthymia Giannitsioti, José M. Miró, Pilar Tornos, Pierre Tattevin, Jacob Strahilevitz, Denis Spelman, Eugene Athan, Francisco Nacinovich, Cláudio Querido Fortes, Cristiane da Cruz Lamas, Bruno Baršić, Nuria Fernández‐Hidalgo, Patricia Muñóz, Vivian H. Chu
201576
10
One Health approach to controlling a Q fever outbreak on an Australian goat farm
Epidemiology and Infection ·Katherine Bond, Gemma Vincent, C.R. Wilks, Lucinda Franklin, Brett Sutton, John Stenos, Raquel Cowan, Kelvin Lim, Eugene Athan, Opusunju Boma Harris, Laura Macfarlane-Berry, Yonatan Segal, Simon M. Firestone
201574
11
The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach
Life Sciences ·Gerwyn Morris, Chiara C. Bortolasci, Basant K. Puri, Lisa Olive, Wolfgang Marx, Adrienne O’Neil, Eugene Athan, André F. Carvalho, Michaël Maes, Ken Walder, Michael Berk
202073
12
Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia
The Medical Journal of Australia ·Paul D. R. Johnson, John Hayman, Tricia Quek, Janet Fyfe, G. Jenkin, John A. Buntine, Eugene Athan, Mike Birrell, Justin Graham, Caroline J. Lavender
200771
13
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
Cytokine ·Gerwyn Morris, Chiara C. Bortolasci, Basant K. Puri, Wolfgang Marx, Adrienne O’Neil, Eugene Athan, Ken Walder, Michael Berk, Lisa Olive, André F. Carvalho, Michaël Maes
202168
14
Once‐Daily Intravenous Cefazolin Plus Oral Probenecid Is Equivalent to Once‐Daily Intravenous Ceftriaxone Plus Oral Placebo for the Treatment of Moderate‐to‐Severe Cellulitis in Adults
Clinical Infectious Diseases ·M. Lindsay Grayson, Malcolm McDonald, Kimberley Gibson, Eugene Athan, Wendy Munckhof, Phillip Paull, Fran Chambers
200267
15
Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population
The Medical Journal of Australia ·Sarah Boyd, Eugene Athan, N. Deborah Friedman, Andrew Hughes, Aaron Walton, Peter Callan, Anthony McDonald, D. O’Brien
201263
16
Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study
ANZ Journal of Surgery ·Kelly Bucca, Ryan Spencer, Neil Orford, Claire Cattigan, Eugene Athan, Anthony McDonald
201258
17
Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update
The Medical Journal of Australia ·D. O’Brien, G. Jenkin, John A. Buntine, Christina M. Steffen, Anthony McDonald, Simon Horne, N. Deborah Friedman, Eugene Athan, Andrew Hughes, Peter Callan, Paul D. R. Johnson
201358
18
Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south‐eastern Australian case series
The Medical Journal of Australia ·D. O’Brien, Andrew Hughes, Allen Cheng, Margaret J. Henry, Peter Callan, Anthony McDonald, Ian Holten, Mike Birrell, John M. Sowerby, Paul D. R. Johnson, Eugene Athan
200757
19
Incidence of Catheter-Related Bloodstream Infection Among Patients With a Needleless, Mechanical Valve–Based Intravenous Connector in an Australian Hematology-Oncology Unit
Infection Control and Hospital Epidemiology ·Kathryn Field, Caroline McFarlane, Allen Cheng, Andrew Hughes, Elly Jacobs, Kaylene Styles, Jillian Low, Peter Stow, Philip Campbell, Eugene Athan
200756
20
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Trials ·Patrick N. A. Harris, Anton Y. Peleg, Jonathan R. Iredell, Paul R. Ingram, Spiros Miyakis, Andrew J. Stewardson, Benjamin A. Rogers, Emma S. McBryde, Jason A. Roberts, Jeffrey Lipman, Eugene Athan, Sanjoy K. Paul, Peter Baker, Tiffany Harris‐Brown, David L. Paterson
201555

About Eugene Athan

Eugene Athan is a scholar working on Epidemiology, Infectious Diseases, Surgery, Small Animals and Molecular Biology, having authored 143 papers that have together received 3.7k indexed citations. Recurring topics across this work include Mycobacterium research and diagnosis (37 papers), Infective Endocarditis Diagnosis and Management (16 papers), Tuberculosis Research and Epidemiology (13 papers), Infectious Diseases and Mycology (12 papers), Antimicrobial Resistance in Staphylococcus (9 papers), Streptococcal Infections and Treatments (8 papers), Antibiotic Resistance in Bacteria (8 papers) and Infectious Diseases and Tuberculosis (8 papers). The work is most often cited by research in Infectious Diseases (1.3k citations), Epidemiology (1.9k citations), Small Animals (448 citations), Applied Microbiology and Biotechnology (108 citations) and Molecular Medicine (199 citations). Eugene Athan has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include D. O’Brien, N. Deborah Friedman, Anthony McDonald, Andrew Hughes, Andrew Hughes, Peter Callan, Aaron Walton, Allen Cheng, Paul D. R. Johnson and Vivian H. Chu. Their work appears in journals such as The Medical Journal of Australia, PLoS neglected tropical diseases, BMC Infectious Diseases, Emerging infectious diseases and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert KrauseBreakdown of academic impact, for papers by Fehmı TabakBreakdown of academic impact, for papers by Antonio ArrietaBreakdown of academic impact, for papers by Jihad BisharaBreakdown of academic impact, for papers by Sang‐Oh LeeBreakdown of academic impact, for papers by D. Rebecca PrevotsBreakdown of academic impact, for papers by Hee Jin CheongBreakdown of academic impact, for papers by V. AusinaBreakdown of academic impact, for papers by I. W. FongBreakdown of academic impact, for papers by Roberto Luzzati